Baillie Gifford & Co. Trims Stock Position in Insulet Corporation $PODD

Baillie Gifford & Co. cut its stake in shares of Insulet Corporation (NASDAQ:PODD) by 2.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,048,369 shares of the medical instruments supplier’s stock after selling 43,329 shares during the period. Baillie Gifford & Co. owned approximately 2.91% of Insulet worth $582,228,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PODD. Robeco Institutional Asset Management B.V. increased its stake in shares of Insulet by 6.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 215,522 shares of the medical instruments supplier’s stock worth $61,260,000 after acquiring an additional 13,508 shares during the period. Trilogy Capital Inc. increased its stake in shares of Insulet by 33.6% during the fourth quarter. Trilogy Capital Inc. now owns 12,457 shares of the medical instruments supplier’s stock worth $3,541,000 after acquiring an additional 3,136 shares during the period. V Square Quantitative Management LLC acquired a new position in shares of Insulet during the fourth quarter worth about $581,000. OFI Invest Asset Management acquired a new position in shares of Insulet during the fourth quarter worth about $134,000. Finally, Ledyard National Bank acquired a new position in shares of Insulet during the fourth quarter worth about $349,000.

Insiders Place Their Bets

In other news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the purchase, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 0.39% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on PODD shares. Citigroup downgraded Insulet from a “buy” rating to a “neutral” rating and cut their target price for the stock from $338.00 to $230.00 in a research note on Tuesday, April 7th. TD Cowen downgraded Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a research note on Monday, January 26th. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research note on Thursday, January 22nd. Evercore cut their target price on Insulet from $340.00 to $240.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Finally, Raymond James Financial cut their target price on Insulet from $385.00 to $355.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. Nineteen analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $342.00.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet named Mike Panos to lead Omnipod commercial execution and growth, a hire that could help accelerate sales execution and product rollout if he delivers on execution targets. Insulet Taps Mike Panos To Drive Omnipod Commercial Execution And Growth
• Positive Sentiment: Some analysts still see large upside (one article cites ~75% upside), suggesting valuation and longer-term growth expectations remain attractive to parts of the sell-side despite recent weakness. Analysts See 75% Upside on Insulet Corporation (PODD) Despite Weak Share Price Momentum
• Neutral Sentiment: Recent writeups examine Insulet’s valuation after the share-price pullback; these provide context for whether current levels offer a buying opportunity versus downside risk. A Look At Insulet (PODD) Valuation After Recent Share Price Weakness
• Neutral Sentiment: The April 10 short-interest data feed shows inconsistent/zero values (likely a reporting error) — treat that specific print cautiously while focusing on the more reliable March figures below.
• Negative Sentiment: Short interest rose in late March to ~3.05M shares (about 4.4% of float), increasing the short-interest ratio to ~3.5 days — higher short interest can amplify downward pressure and volatility.
• Negative Sentiment: Citigroup downgraded PODD to Neutral, and Evercore cut its price target to $240 — analyst downgrades and lower targets are primary drivers of selling pressure. Citigroup Downgrades Insulet (NASDAQ:PODD) to Neutral Evercore Cuts Insulet (NASDAQ:PODD) Price Target to $240.00
• Negative Sentiment: Multiple headlines note that PODD has hit new 52-week/12-month lows after analyst actions, signaling bearish momentum and potential stop-loss triggers for some holders. Insulet (NASDAQ:PODD) Hits New 12-Month Low on Analyst Downgrade Insulet Corp. stock falls to new 52-week low
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Insulet, introducing potential litigation risk and an additional overhang for the stock until resolved. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation – PODD

Insulet Stock Performance

NASDAQ PODD opened at $196.93 on Monday. Insulet Corporation has a 1-year low of $195.28 and a 1-year high of $354.88. The company has a market capitalization of $13.64 billion, a P/E ratio of 56.27, a PEG ratio of 1.18 and a beta of 1.47. The business has a 50 day moving average price of $232.25 and a 200 day moving average price of $279.24. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. During the same period last year, the business posted $1.15 EPS. Insulet’s quarterly revenue was up 31.2% on a year-over-year basis. Sell-side analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.